AbbVie’s emraclidine trials for schizophrenia failed to meet PANSS score improvement at week 6. Despite this setback, analyst says the Cerevel acquisition still holds promise, with other treatments.

(RTTNews) - Biopharmaceutical company AbbVie, Inc. (ABBV) announced Monday that its two Phase 2 EMPOWER trials investigating emraclidine as a once-daily, oral monotherapy treatment for adults with ...

Truist analyst Srikripa Devarakonda notes that AbbVie (ABBV) announced negative trial results for emraclidine in dual Phase 2 schizophrenia trials, which the firm sees as a negative for AbbVie and a ...

AbbVie (NYSE:ABBV) will report Q4 2024 results next week and provide guidance for 2025. The company is handling the erosion of Humira quite well, but the trajectory of the decline in Humira's net ...

In a regulatory filing, AbbVie (ABBV) stated, “On January 9, 2025, AbbVie determined that it will record an impairment charge related to the emraclidine intangible asset acquired as part of the ...

AbbVie's strong results, pipeline wins, and Rinvoq exclusivity boost its outlook. Read the latest analysis on ABBV stock here ...

On Monday, AbbVie Inc (NYSE:ABBV) stock plunged after two trials investigating emraclidine as a once-daily, oral monotherapy treatment for adults with schizophrenia failed two Phase 2 trials. The ...

A once-promising developmental schizophrenia drug didn't perform well in recent testing. It failed to meet its primary endpoint in a phase 2 clinical trial. A splashy recent acquisition by the company ...

AbbVie’s ABBV shares rose 3.0% on Friday after Leerink Partners analyst, David Risinger, upgraded his rating on the stock from Market Perform to Outperform. Excluding Friday’s movement, AbbVie stock ...

Dec 7 (Reuters) - AbbVie's (ABBV.N), opens new tab decision to buy Cerevel Therapeutics (CERE.O), opens new tab before key data on the drug developer's experimental schizophrenia treatment may have ...

AbbVie’s (ABBV) two Phase 2 EMPOWER trials investigating emraclidine as a once-daily, oral monotherapy treatment for adults with schizophrenia who are experiencing an acute exacerbation of psychotic ...